Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 2,844

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Greenberg, Peter L., Tuechler, Heinz, Schanz, Julie, Sanz, Guillermo, Garcia-Manero, Guillermo, Solé, Francesc, Bennett, John M., Bowen, David, Fenaux, Pierre, Dreyfus, Francois, Kantarjian, Hagop, Kuendgen, Andrea, Levis, Alessandro, Malcovati, Luca, Cazzola, Mario, Cermak, Jaroslav, Fonatsch, Christa, Le Beau, Michelle M., Slovak, Marilyn L., Krieger, Otto, Luebbert, Michael, Maciejewski, Jaroslaw, Magalhaes, Silvia M. M., Miyazaki, Yasushi, Pfeilstöcker, Michael, Sekeres, Mikkael, Sperr, Wolfgang R., Stauder, Reinhard, Tauro, Sudhir, Valent, Peter, Vallespi, Teresa, van de Loosdrecht, Arjan A., Germing, Ulrich, Haase, Detlef·2012·Blood
DOI 10.1182/blood-2012-03-420489
Open this paper in CoChat — free account

Abstract

The International Prognostic Scoring Sytem (IPSS) is an important standard for ssessing prognosis of primary untreated adult patients with myelodysplastic syndromes (MDS). To refine the IPSS, MDS patient databases from international institutions were coalesced to assemble a much larger combined database (Revised-IPSS [IPSS-R], n = 7012, IPSS, n = 816) for analysis. Multiple statistically weighted clinical features were used to generate a prognostic categorization model. Bone marrow cytogenetics, marrow blast percentage, and cytopenias remained the basis of the new system. Novel components of the current analysis included: 5 rather than 3 cytogenetic prognostic subgroups with specific and new classifications of a number of less common cytogenetic subsets, splitting the low marrow blast percentage value, and depth of cytopenias. This model defined 5 rather than the 4 major prognostic categories that are present in the IPSS. Patient age, performance status, serum ferritin, and lactate dehydrogenase were significant additive features for survival but not for acute myeloid leukemia transformation. This system comprehensively integrated the numerous known clinical features into a method analyzing MDS patient prognosis more precisely than the initial IPSS. As such, this IPSS-R should prove beneficial for predicting the clinical outcomes of untreated MDS patients and aiding design and analysis of clinical trials in this disease.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2012-03-420489

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 45

  1. Malcovati, 2005, Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria, a basis for clinical decision making., J Clin Oncol, 23, 7594, 10.1200/JCO.2005.01.7038 · DOI
  2. Malcovati, 2007, Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes., J Clin Oncol, 25, 3503, 10.1200/JCO.2006.08.5696 · DOI
  3. Kantarjian, 2008, Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System., Cancer, 113, 1351, 10.1002/cncr.23697 · DOI
  4. Della Porta, 2011, Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome., Haematologica, 96, 441, 10.3324/haematol.2010.033506 · DOI
  5. Vardiman, 2009, The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia, rationale and important changes., Blood, 114, 937, 10.1182/blood-2009-03-209262 · DOI
  6. Bennett, 1982, Proposals for the classification of the myelodysplastic syndromes., Br J Haematol, 51, 189, 10.1111/j.1365-2141.1982.tb08475.x · DOI
  7. Schanz, 2012, New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes and oligoblastic AML following MDS derived from an international database merge., J Clin Oncol, 30, 820, 10.1200/JCO.2011.35.6394 · DOI
  8. Wimazal, 2001, Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes., Leuk Res, 25, 287, 10.1016/S0145-2126(00)00140-5 · DOI
  9. Germing, 2005, Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes., Leukemia, 19, 2223, 10.1038/sj.leu.2403963 · DOI
  10. Wimazal, 2008, Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes., Ann Oncol, 19, 970, 10.1093/annonc/mdm595 · DOI
  11. Sanz, 2008, Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]., Blood, 112, 10.1182/blood.V112.11.640.640 · DOI
  12. Gatto, 2003, Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)., Blood, 102, 1622, 10.1182/blood-2002-10-3264 · DOI
  13. Neumann, 2009, Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia., Leuk Res, 33, 232, 10.1016/j.leukres.2008.06.003 · DOI
  14. Verburgh, 2003, Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes., J Clin Oncol, 21, 273, 10.1200/JCO.2003.04.182 · DOI
  15. Buesche, 2008, Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes., Leukemia, 22, 313, 10.1038/sj.leu.2405030 · DOI
  16. Della Porta, 2009, Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes., J Clin Oncol, 27, 754, 10.1200/JCO.2008.18.2246 · DOI
  17. Wang, 2009, Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes., Leuk Res, 33, 1594, 10.1016/j.leukres.2009.02.005 · DOI
  18. Naqvi, 2011, Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model., J Clin Oncol, 29, 2240, 10.1200/JCO.2010.31.3353 · DOI
  19. Pfeilstöcker, 2012, Time changes in predictive power of established and recently proposed clinical, cytogenetic and comorbidity scores for myelodysplastic syndromes., Leuk Res, 36, 132, 10.1016/j.leukres.2011.09.007 · DOI
  20. Shaffer, 2009, An International System for Human Cytogenetic Nomenclature: Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature
  21. Grambsch, 1995, Diagnostic plots to reveal functional form for covariates in multiplicative intensity models., Biometrics, 51, 1469, 10.2307/2533277 · DOI
  22. Minder, 1996, A robust method for proportional hazards regression., Stat Med, 15, 1033, 10.1002/(SICI)1097-0258(19960530)15:10<1033::AID-SIM215>3.0.CO;2-Y · DOI
  23. Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors., Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 · DOI
  24. Kao, 2008, Impact of cytopenias on clinical outcomes in myelodysplastic syndrome., Am J Hematol, 83, 765, 10.1002/ajh.21249 · DOI
  25. Malcovati, 2011, Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS)., Haematologica, 96, 1433, 10.3324/haematol.2011.044602 · DOI
  26. Sanz, 1989, Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients., Blood, 74, 395, 10.1182/blood.V74.1.395.395 · DOI
  27. Cordoba, 2012, The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome., Leuk Res, 36, 287, 10.1016/j.leukres.2011.10.025 · DOI
  28. Kantarjian, 2007, The incidence and impact of thrombocytopenia in myelodysplastic syndromes., Cancer, 109, 1705, 10.1002/cncr.22602 · DOI
  29. Aul, 1992, Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system., Leukemia, 6, 52
  30. Gonzalez-Porras, 2011, Spanish Myelodysplastic Syndrome Registry: prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome., Cancer, 117, 5529, 10.1002/cncr.26173 · DOI
  31. Morel, 1996, Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques., Br J Haematol, 94, 116, 10.1046/j.1365-2141.1996.6122056.x · DOI
  32. Kuendgen, 2006, Myelodysplastic syndromes in patients younger than age 50., J Clin Oncol, 24, 5358, 10.1200/JCO.2006.07.5598 · DOI
  33. Nösslinger, 2010, Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes., Ann Oncol, 21, 120, 10.1093/annonc/mdp264 · DOI
  34. Stauder, 2008, Impact of age and comorbidity in myelodysplastic syndromes., J Natl Compr Canc Netw, 6, 927, 10.6004/jnccn.2008.0070 · DOI
  35. Zipperer, 2009, The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome., Haematologica, 94, 729, 10.3324/haematol.2008.002063 · DOI
  36. Sperr, 2010, Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core data set of 582 patients of the Austrian MDS Platform., Ann Oncol, 21, 114, 10.1093/annonc/mdp258 · DOI
  37. Park, 2011, Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS., Leuk Res, 35, 1530, 10.1016/j.leukres.2011.07.007 · DOI
  38. Deeg, 2000, Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome., Leuk Lymphoma, 37, 405, 10.3109/10428190009089441 · DOI
  39. Verma, 2005, Cytokine targets in the treatment of myelodysplastic syndromes., Curr Hematol Rep, 4, 429
  40. Greenberg, 2011, NCCN Practice Guidelines for in Oncology: myelodysplastic syndromes., J Natl Compr Canc Netw, 9, 30, 10.6004/jnccn.2011.0005 · DOI
  41. Smith, 2003, Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series., Blood, 102, 43, 10.1182/blood-2002-11-3343 · DOI
  42. Walter, 2012, Clonal architecture of secondary acute myeloid leukemia., N Engl J Med, 366, 1090, 10.1056/NEJMoa1106968 · DOI
  43. van de Loosdrecht, 2008, Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry., Blood, 111, 1067, 10.1182/blood-2007-07-098764 · DOI
  44. Westers, 2012, Standardization of flow cytometry in myelodysplastic syndromes: a report from an International Consortium and the European LeukemiaNet Working Group., Leukemia, 26, 1730, 10.1038/leu.2012.30 · DOI
  45. Greenberg, 2011, Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM) [abstract]., Leuk Res, 35, S6, 10.1016/S0145-2126(11)70016-9 · DOI

Cited by

See all 2,844

Metadata

Authors
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., Kantarjian, H., Kuendgen, A., Levis, A., Malcovati, L., Cazzola, M., Cermak, J., Fonatsch, C., Le Beau, M. M., Slovak, M. L., Krieger, O., Luebbert, M., Maciejewski, J., Magalhaes, S. M. M., Miyazaki, Y., Pfeilstöcker, M., Sekeres, M., Sperr, W. R., Stauder, R., Tauro, S., Valent, P., Vallespi, T., van de Loosdrecht, A. A., Germing, U., & Haase, D.
Affiliations
  • Stanford University Cancer Center, Stanford, CA;
  • Hanusch Hospital, Boltzmann Institute for Leukemia Research, Vienna, Austria;
  • Georg August Universität, Göttingen, Germany;
  • Hospital Universitario La Fe, Valencia, Spain;
  • The University of Texas, MD Anderson Cancer Center, Houston, TX;
  • Hospital del Mar, Barcelona, Spain;
  • James P. Wilmont Cancer Center, University of Rochester Medical Center, Rochester, NY;
  • St James's University Hospital, Leeds, United Kingdom;
  • Hôpital Avicenne, Assistance Publique–Hôpitaux de Paris (AP-HP)/University Paris XIII, Bobigny, France;
  • Hôpital Cochin, AP-HP University of Paris V, Paris, France;
  • Heinrich-Heine University Hospital, Düsseldorf, Germany;
  • Antonio e Biagio e C Arrigo Hospital, Alessandria, Italy;
  • Fondazione Istituti di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo and University of Pavia, Pavia, Italy;
  • Institute of Hematology and Blood Transfusion, Praha, Czech Republic;
  • Medical University of Vienna, Vienna, Austria;
  • University of Chicago Comprehensive Cancer Research Center, Chicago, IL;
  • Quest Diagnostics Nichols Institute, Chantilly, VA;
  • Elisabethinen Hospital, Linz, Austria;
  • University of Freiburg Medical Center, Freiburg, Germany;
  • Cleveland Clinic, Cleveland, OH;
  • Federal University of Ceara, Fortaleza, Brazil;
  • Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan;
  • University Hospital of Innsbruck, Innsbruck, Austria;
  • University of Dundee, Scotland, United Kingdom;
  • Hospital Universitario Vall d'Hebron, Barcelona, Spain; and
  • VU University Medical Center, Amsterdam, The Netherlands
Venue
Blood
Publisher
American Society of Hematology
Published
2012-09-20
Volume
120
Issue
12
Pages
2454-2465
ISSN
  • 0006-4971
  • 1528-0020
DOI
10.1182/blood-2012-03-420489
Cited by
2,844
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review